Table 1.
Ongoing clinical trials in HLRCC and FHdRCC. .
| Study number | Agents | Phase | Primary endpoint | Therapy setting | Status |
|---|---|---|---|---|---|
| HLRCC | |||||
| NCT04981509 | bevacizumab + erlotinib + atezolizumab | II | CR | second line | recruiting |
| NCT04603365 | pamiparib + temozolomide | II | ORR | second line | recruiting |
| NCT02495103 | vandetanib + metformin | I/II | MTD/ORR | second line | terminated |
| NCT01130519 | bevacizumab + erlotinib | II | ORR | first/second line | active, not recruiting |
| FHdRCC | |||||
| NCT04068831 | talazoparib + avelumab | II | ORR | second line | recruiting |
| NCT04387500 | sintilimab + axitinib | II | PFS, ORR | first line | recruiting |
| NCT04146831 | sintilimab | II | PFS | second line | not yet recruiting |
CR, complete response; ORR, objective response rate; PFS, progression-free survival; MTD, maximum tolerated dose. Status according to clinicaltrials.gov assessed on 08th February 2022.